This Impact Report highlights our work in financial year 2026 (FY26) to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work. Our $12.1m contributed to science and innovation to advance knowledge, research and careers in biomedicine. 114m doses of seasonal influenza vaccine distributed globally. 41 clinical trials in operation across all therapeutic areas. $28m contributed to support patient communities. ~$6m in economic activity per donor centre. $2.1m in contributions to local communities. 83 major regulatory approvals. 6 | CSL IMPACT REPORT 2026 ~8.3m patients treated with plasmaderived and recombinant therapies. 120+ countries make use of CSL’s lifesaving vaccines and medicines | Introduction | For Patients | For Science | For Society | Looking Ahead
RkJQdWJsaXNoZXIy MjE2NDg3